Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment
In adult patients with cystic fibrosis (CF) fraction of exhaled nitric oxide (FeNO) has been reported to be normal or abnormally low [1]. FeNO has also been reported to correlate with spirometry [2–4], and to increase following treatment with ivacaftor [5, 6], suggesting that FeNO could be used as a noninvasive, fast and easily available marker of CFTR-function. The aim of this study was to examine whether in adult CF patients, FeNO was associated with patient characteristics and lung function, and whether FeNO was affected by acute exacerbation. We also aimed to examine FeNO evolution over a longer period after starting cystic fibrosis transmembrane conductance regulator (CFTR)-modifying treatment (ivacaftor and ivacaftor/lumacaftor).
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Vincken, S., Verbanck, S., De Wachter, E., Vanderhelst, E. Tags: Original Articles: Research letters Source Type: research